Co-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF Base
Co-Diagnostics (Nasdaq: CODX) announced the first international deployment of its Vector Smart® mosquito surveillance platform at an overseas United States Air Force base, including laboratory equipment, consumables and mosquito abatement reagents.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Co-Diagnostics (Nasdaq: CODX) announced the first international deployment of its Vector Smart® mosquito surveillance platform at an overseas United States Air Force base, including laboratory equipment, consumables and mosquito abatement reagents. This step follows domestic growth to 40 customers in 21 U.S. states and marks the product line’s first international expansion. Vector Smart multiplex PCR assays are designed to detect mosquito-borne pathogens such as West Nile virus, Eastern and Western equine encephalitis, St. Louis encephalitis, Zika, dengue and chikungunya, helping abatement districts improve situational awareness and the efficiency of control efforts.
Details
Market move: CODX -4.03% in the Sep 1 session. Vector Smart international deployment
On Sep 1, the day this news came out, CODX closed 4.03% below the previous close. Argus tracked a trough of -3.4% from its starting point during tracking. Our momentum scanner recorded 5 alerts for this stock that day.
Data tracked by StockTitan Argus for the Sep 1 session.
Key Figures
- Customers
- 40 customers
- Vector Smart business
- U.S. States Served
- 21 U.S. states
- Domestic Vector Smart expansion
Historical Context
-
Roundtable participation and previously submitted 510(k) notification drew a negative reaction.
-
Quarterly revenue remained minimal while net loss and cash balances deteriorated.
-
FDA 510(k) and CLIA waiver submissions advanced testing toward possible commercialization.
-
Scheduled second-quarter results and webcast preceded a modestly positive price reaction.
-
Ebola test-kit supply and proof-of-concept work preceded the period's sharpest decline.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
multiplex pcr assays medical
mosquito abatement technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Shipments of laboratory equipment and other mosquito abatement materials to overseas USAF base represent first international expansion of Vector Smart product line
"Vector Smart continues to demonstrate the versatility of our molecular diagnostics technology and the growing demand for decentralized surveillance solutions," said Dwight Egan, Chief Executive Officer of Co-Diagnostics. "We saw a significant unmet need for rapid, local mosquito surveillance that can provide public health officials with timely, actionable information, so we built a platform to address it. As we continue expanding into additional government, military and public health markets, we believe Vector Smart is well positioned to become an increasingly important contributor to our long-term commercialization strategy while further validating the breadth of Co-Dx technology."
This deployment follows continued domestic expansion of the Company's Vector Smart business, which has served 40 customers across 21 U.S. states, and represents the first international expansion of the product line. Co-Dx Vector Smart products include multiplex PCR assays for mosquito surveillance designed to detect pathogens associated with diseases like West Nile virus, Eastern and Western equine encephalitis,
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will," "seeks," "anticipates," and similar expressions, or the negative of these terms. Forward-looking statements in this press release include, but are not limited to statements regarding: (i) Vector Smart's positioning to become an important contributor to the Company's long-term commercialization strategy; and (ii) expectations regarding continued expansion into government, military, and public health markets. Such statements are subject to a number of risks and uncertainties, including, without limitation risks related to the performance, reliability, and market acceptance of the Co-Dx Vector Smart tests and other Co-Dx technology; risks associated with dependence on third parties, suppliers, collaborators, and distribution partners; risks related to competition, technological change, and intellectual property protection; and other risks described from time to time in the Company's filings with the Securities and Exchange Commission ("SEC"). Actual results may differ materially from those expressed or implied in these forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. A further description of risks and uncertainties can be found in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2026, Quarterly Reports on Form 10-Q, and in its other filings with the SEC. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-expands-vector-smart-customer-reach-with-first-international-installation-in-usaf-base-302865873.html
SOURCE Co-Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.